Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

• Main Authors: Karin Nelander (Author), Maria Lagerstrom‐Fermer (Author), Carl Amilon (Author), Erik Michaëlsson (Author), Maria Heijer (Author), Magnus Kjaer (Author), Muir Russell (Author), David Han (Author), Eva‐Lotte Lindstedt (Author), Carl Whatling (Author), Li‐Ming Gan (Author), Hans Ericsson (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single‐blind, placebo‐controlled study, following once‐daily multiple ascending dosing to steady‐state in healthy subjects. Target engagement was...